Skip to main content
Figure 3 | BMC Pulmonary Medicine

Figure 3

From: Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial

Figure 3

Change from baseline in exercise endurance time at Week 3. Change from baseline in exercise endurance time during constant work rate cycle ergometry to symptom limitation at 75% of the maximum work rate was assessed at Week 3 (ITT population). Data reported as least squares means change from baseline (analysis of covariance) + standard error; Δ = least squares means difference (95% confidence interval). *p < 0.05 versus placebo. BID, twice daily; ITT, intent-to-treat.

Back to article page